IEM-2163

IEM-2163 is an experimental small molecule and a guanidine derivative of adamantane, specifically identified as 3,5-dimethyl-1-adamantylguanidine hydrochloride. It functions as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, structurally related to the antiparkinsonian agents memantine and amantadine. Developed by researchers at the Institute of Experimental Medicine, IEM-2163 has been investigated for its neuroprotective and symptomatic effects in Parkinson's disease. In preclinical studies using rotenone-induced parkinsonism models in rats, IEM-2163 demonstrated significant antiparkinsonian activity, outperforming both levodopa and memantine in reducing severe oligokinesia and eliminating catalepsy. Its pharmacological profile suggests it may provide a more potent or safer alternative to traditional aminoadamantanes by modulating glutamatergic neurotransmission.

Other names

3,5-dimethyl-1-adamantylguanidine hydrochloride3,5-dimethyladamant-1-ylguanidine hydrochloride1-(3,5-dimethyladamantan-1-yl)guanidine hydrochloride